NAVELBINE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug NAVELBINE contains one active pharmaceutical ingredient (API):

1	Vinorelbine UNII 253GQW851Q - VINORELBINE TARTRATE
	Vinorelbine is an antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids. Vinorelbine inhibits tubulin polymerization and blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.
	Read more about Vinorelbine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CA04	Vinorelbine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CA Vinca alkaloids and analogues
Discover more medicines within L01CA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4620E, 7263G, 9009E, 9010F
BR	Câmara de Regulação do Mercado de Medicamentos	507003601152310, 507003602159319, 507003603112316, 507003604119314
EE	Ravimiamet	1039979, 1069602, 1456411, 1456422, 1595594, 1595606
ES	Centro de información online de medicamentos de la AEMPS	59300, 65978, 65979
FI	Lääkealan turvallisuus- ja kehittämiskeskus	002943, 003164, 003175, 168997, 169433
FR	Base de données publique des médicaments	61168991, 63413635, 64503288, 68184425
GB	Medicines & Healthcare Products Regulatory Agency	155170, 48043, 48044, 95226, 95229
HK	Department of Health Drug Office	44009, 56212, 56213
IE	Health Products Regulatory Authority	88431, 88492
IL	מִשְׂרַד הַבְּרִיאוּת	6500, 6504
IT	Agenzia del Farmaco	027865106, 027865118
JP	医薬品医療機器総合機構	4240407A1028, 4240407A2024
LT	Valstybinė vaistų kontrolės tarnyba	1004236, 1004237, 1065716, 1065717, 1067907, 1067908
MT	Medicines Authority	AA565/73701
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	625M2003
NL	Z-Index G-Standaard	14645971, 14646005
NL	Z-Index G-Standaard, PRK	118109, 118117, 58815, 58823
NZ	Medicines and Medical Devices Safety Authority	11625, 11626, 7690
PL	Rejestru Produktów Leczniczych	100046499, 100108817, 100108823
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W42512001, W42512002, W42513001, W42513002
SG	Health Sciences Authority	06778P, 12546P, 12547P
TN	Direction de la Pharmacie et du Médicament	6063121H, 6063124H, 6063125H, 6063126H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699749190039, 8699749190046, 8699749770019, 8699749770026
US	FDA, National Drug Code	64370-532
ZA	Health Products Regulatory Authority	30/26/0123, 30/26/0124, 36/26/0012, 36/26/0013, 36/26/0014, 36/26/0015